OBSERVE MEDICAL ASA (OBSRV.OL)
Every figure this model derived for OBSRV.OL, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2023-12-31.
The figures, and where each came from
This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.
| Figure | Value | XBRL tag | As at |
|---|---|---|---|
| cash | 13,676,000 | CashAndCashEquivalents |
2024-01-01 |
| current assets | 27,222,000 | CurrentAssets |
2024-01-01 |
| current liabilities | 60,883,000 | CurrentLiabilities |
2024-01-01 |
| equity | 115,606,000 | Equity |
2024-01-01 |
| interest expense | 16,605,000 | FinanceCosts |
2023-12-31 |
| ocf | -24,455,000 | CashFlowsFromUsedInOperatingActivities |
2023-12-31 |
| revenue | 27,942,000 | Revenue |
2023-12-31 |
The ratios
The figures themselves rather than their scores — what somebody looking up OBSRV.OL on one particular measure came for.
| Ratio | Value |
|---|---|
| cash operating margin | -183.46 |
| current ratio | 0.45 |
| current ratio reported | 0.45 |
| fcf margin | -87.52 |
| growth cv | 1.35 |
| interest cover | -3.09 |
| operating margin | -183.46 |
| owner earnings margin | -87.52 |
| revenue growth | 43.14 |
| revenue growth per share | 43.14 |
| roic | -26.65 |
| rule of 40 | -140.32 |
| sbc pct revenue | 0.0 |
What to be careful about
What this model itself distrusts about OBSRV.OL's figures. Written by the derivation as it ran, not added afterwards.
- newest fact in the filing is 2024-01-01 (2y old); this company's data is not usable and the scores below should be ignored
- revenue is annual, not TTM
- operating income is annual, not TTM
- revenue period ends 2023-12-31 (991 days ago) - the tag chain found nothing recent, so treat this row as unscored
- no current stock compensation tagged; treated as zero, so owner earnings are overstated
- no current capital expenditure tagged; treated as zero, so free cash flow is overstated and equals operating cash flow
- no market cap; set `market_cap` in overrides.yaml
- no usable diluted share count, so growth is measured on total revenue rather than per share; a company issuing shares to fund that growth reads better than it is
- no forward EPS estimate; growth rests on filings only. Analyst consensus is not published in XBRL, so it has to be fetched from a data provider or set by hand in overrides.yaml as `eps_growth_2y`
- valuation DROPPED from the total: only 0 of 2 inputs could be computed (ev sales, ev owner earnings not tagged), so the score is not meaningful. Its weight is spread over the other dimensions
- durability rests on 3 of 4 inputs; not tagged: contracted coverage
- growth rests on 3 of 4 inputs; not tagged: sustained growth